官网首页 › 研究观点 › 观点正文

华东医药2025中报解读:创新药成增长引擎,医美业务何时回暖?

发布于 2025-09-03

<blockquote style="margin: 6px 0px;padding: 6px 12px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;border-left: 4px solid rgba(0, 0, 0, 0.08);color: rgb(0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-size: medium;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;"><span leaf="">国内医药行业领军企业华东医药交出了一份颇具看点的半年成绩单,创新药业务以</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">59%的惊人增速</span></strong><span leaf="">成为最大亮点。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p></blockquote><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">8月下旬,华东医药发布了2025年半年度财务报告。数据显示,公司上半年实现营业收入217亿元,同比增长3.4%;净利润18亿元,同比增长7.0%。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这份成绩单超出了市场预期,尤其是在医药行业整体面临挑战的背景下显得尤为难得。</span></p><hr style="margin: 16px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;border-width: 0.5px 0px 0px;border-right-style: initial;border-bottom-style: initial;border-left-style: initial;border-right-color: initial;border-bottom-color: initial;border-left-color: initial;border-image: initial;border-top-style: solid;border-top-color: rgba(0, 0, 0, 0.08);color: rgb(0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-size: medium;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;" /><h2 style="margin-top: 0px !important;margin-right: 0px;margin-bottom: 0px;margin-left: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">01 业务板块分化明显,创新药成最大亮点</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">从业务板块来看,华东医药三大业务线表现各异。医药制造业务同比增长9.2%,医药商业业务增长2.8%,而医美业务则表现不佳,国际和中国市场分别下滑8.0%和12.1%。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">最引人注目的是创新药的表现。上半年创新药收入达到11亿元,</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">同比大幅增长59%</span></strong><span leaf="">,占制药业务收入的14.8%。这个数字不仅体现了华东医药转型创新的决心,也展示了公司研发投入的成果。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">华东医药在研发上的投入可谓大手笔。上半年研发费用达到10亿元,同比增长55%,这表明公司正在坚定不移地向创新驱动转型。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">02 创新转型成效显著,多款新药即将放量</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">华东医药的创新转型正在步入收获期。公司管理层在业绩说明会上透露,2025年下半年将有多个重要催化剂:</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">首先是新药获批上市。</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">迈菲尼(mefinib)和MB-102</span></strong><span leaf="">两款新药预计将获得国家药监局批准,为公司带来新的增长点。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">其次是新产品的销售放量。包括乌司奴单抗、Elahere(FRα ADC)和CT053(BCMA CAR-T)等多款创新药将在下半年加速市场推广。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">此外,华东医药还将在ASH和ADA等国际学术会议上公布10多项临床数据,包括HDM2005(ROR1 ADC)的Ⅰa期数据和HDM1005(GLP1/GIP)的数据。这些数据的公布将进一步增强投资者对公司创新管线的信心。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">03 对外授权合作加速,GLP-1和ADC成焦点</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">对外授权合作(BD)方面,华东医药正在积极推进关键管线的开发,以优化潜在的合作条款。公司特别指出,在GLP-1和多个ADC资产方面具有BD潜力,并且一直在与跨国药企合作伙伴保持密切沟通。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这种开放合作的态度值得赞赏。通过与国际巨头合作,华东医药不仅能够获得前期授权费用和里程碑付款,还能借助合作伙伴的全球商业化网络,实现产品价值的最大化。</span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">04 医美业务面临挑战,新品布局未来</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">相比之下,华东医药的医美业务仍然面临较大挑战。国内医美行业经营环境依然困难,公司预计下半年将较上半年有所改善,但全面复苏仍需时日。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">管理层表示,目标是实现中国市场正增长,并缩小海外业务亏损。为达成这一目标,公司计划在2026-2027年在中国市场推出多款新产品,包括Ellanough M、重组肉毒素、迈利精确、Lanuma和V30等。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这些新品的推出将丰富华东医药的医美产品线,增强市场竞争力。但考虑到医美行业监管趋严和竞争加剧的现状,该业务能否重回高速增长轨道仍需观察。</span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">05 机构上调目标价,未来增长可期</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">基于华东医药的创新转型进展和未来增长潜力,UBS分析师将公司目标价从50.00元上调至56.60元,并维持“买入”评级。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这一目标价是基于DCF估值模型得出,假设条件包括更高的制药业务收入增长率和经营利润率(得益于业务结构优化)。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">分析师还调整了对公司2025-2027年的业绩预测,将收入预期提高了3%/1%/1%,每股收益(EPS)预期提高了20%/14%/9%。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">估值上调的主要理由包括:公司核心产品百令胶囊、灵骨补和塔克莫司预计将减少收入下降(因为这些产品近期不受集采影响);以及对森那普利(PARP抑制剂)、janagilifzin proline和收购的衡霸子公司业绩的预期。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">06 投资价值分析,长期前景看好</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">从投资角度看,华东医药当前市值约803亿元,动态市盈率21.7倍,处于合理区间。公司预计2025年每股收益为2.11元,2026年将增长至2.24元,2027年进一步增至2.49元。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">华东医药的股东回报也值得关注。公司近年来分红比例稳步提升,预计2025年每股股利为0.84元,股息收益率约1.8%,为投资者提供了稳定的现金流。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">从业务结构来看,华东医药已经形成了创新药、仿制药、医药商业和医美四大板块协同发展的格局。这种多元化的业务结构既保证了短期业绩的稳定性,又为长期增长提供了多个引擎。</span></p><hr style="margin: 16px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;border-width: 0.5px 0px 0px;border-right-style: initial;border-bottom-style: initial;border-left-style: initial;border-right-color: initial;border-bottom-color: initial;border-left-color: initial;border-image: initial;border-top-style: solid;border-top-color: rgba(0, 0, 0, 0.08);color: rgb(0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-size: medium;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;" /><p style="margin-top: 0px !important;margin-right: 0px;margin-bottom: 0px;margin-left: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">随着多款创新药在2025年下半年获批上市和放量销售,华东医药的</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">创新药收入占比有望突破20%</span></strong><span leaf="">。公司已经从传统仿制药企业成功转型为创新驱动型医药企业。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">未来三到五年,华东医药的创新管线将进一步丰富,对外合作也有望取得突破。在集采常态化的背景下,这种创新转型不仅必要,而且将决定公司能否在激烈的市场竞争中保持领先地位。</span></p><section><span leaf=""><br /></span></section><p style="display: none;"><mp-style-type data-value="3"></mp-style-type></p>

← 返回观点全库